RecruitingNCT07343193

Deprescribing Antipsychotics: a Multiple Case Study


Sponsor

University Hospital, Strasbourg, France

Enrollment

30 participants

Start Date

Sep 9, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations encountered in daily practice: who should be deprescribed, when, at what rate, what strategy to employ in case of relapse, etc. The fear of relapse leads psychiatrists (particularly in France) to tend to maintain long-term treatment, even if the arguments for this maintenance may be debatable due to an uncertain benefit-risk balance. Conversely, patients often request a reduction or discontinuation, notably because of the side effects of the treatments. This argument serves to justify the value of presenting unique clinical situations like those in this study in a publication. The goal is for readers to gain a practical understanding of the successes and difficulties of deprescribing in real-life situations.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Adults (≥18 years)
  • Patients with a psychotic or related disorder
  • Patients on long-term antipsychotic treatment, clinically stable, who accept or request a deprescription between January 1, 2021, and October 30, 2025

Exclusion Criteria1

  • \- Patients who have expressed their opposition to participating in the study

Locations(1)

Service de Psychiatrie 1 - CHU de Strasbourg - France

Strasbourg, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07343193


Related Trials